+91-98 455 710 46 | info@nckpharma.com
Day

May 27, 2019

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused...
Read More

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!